Date:____Oct. 21th, 2022____ Your Name:____Houqiang Li_ Manuscript Title:__ Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|--|---------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | XNone |
| | testimony | |
| | | |
| 7 | Support for attending | XNone |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| • | pending | |
| | P | |
| _ | | |
| 9 | Participation on a Data | XNone |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X_None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | XNone |
| | | |
| | | |
| 12 | Receipt of equipment, | X None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 12 | | V. Nono |
| 13 | Other financial or non- financial interests | XNone |
| | | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date:____ Oct. 21th, 2022____ Your Name:____ Wenmiao Wang _ Manuscript Title:__ Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|------------------------------|--------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | X None |
| - | testimony | |
| | | |
| 7 | Support for attending | X None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | XNone |
| | pending | |
| | | |
| 9 | Participation on a Data | X None |
| 5 | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | | V News |
| 10 | Leadership or fiduciary role | X_None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | XNone |
| | | |
| | | |
| 12 | Receipt of equipment, | X None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| | | |
| 13 | Other financial or non- | X_None |
| | financial interests | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date:_____ Oct. 21th, 2022____

Your Name:___ Zhanghao Huang

Manuscript Title:__Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):

Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | (HS2019001) Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: past 36 monthsX_None | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|------------------------------|--------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | X None |
| - | testimony | |
| | | |
| 7 | Support for attending | X None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | XNone |
| | pending | |
| | | |
| 9 | Participation on a Data | X None |
| 5 | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | | V News |
| 10 | Leadership or fiduciary role | X_None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | XNone |
| | | |
| | | |
| 12 | Receipt of equipment, | X None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| | | |
| 13 | Other financial or non- | X_None |
| | financial interests | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 21th, 2022

Your Name: Peng Zhang

Manuscript Title:__Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):

Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----------|--|--------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | X None |
| 0 | testimony | |
| | testimony | |
| 7 | Support for attending | X None |
| <i>'</i> | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| | | |
| 9 | Participation on a Data | X None |
| 9 | Safety Monitoring Board or Advisory Board | |
| | | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | X None |
| .= | | |
| | | |
| 12 | Receipt of equipment, | X None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | X None |
| 10 | financial interests | |
| | | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date:_____Oct. 21th, 2022_____ Your Name:___ Lei Liu Manuscript Title:__Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.___ Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|------------------------------|--------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | X None |
| Ũ | testimony | |
| | | |
| 7 | Support for attending | X None |
| ' | meetings and/or travel | |
| | meetings and/or traver | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| | | |
| | | |
| 9 | Participation on a Data | X_None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | XNone |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | X None |
| | | |
| | | |
| 42 | | |
| 12 | Receipt of equipment, | X_None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | X None |
| 13 | financial interests | |
| | | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date:_____ Oct. 21th, 2022_____

Your Name:___ Xinyu Sha

Manuscript Title: Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.

Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|--|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong | Provide financial or technical support for this article Provide financial or technical support for this article |
| | No time limit for this item. | (HS2019001) Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: past 36 monthsX_None | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|------------------------------|---------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | X None |
| _ | testimony | |
| | - / | |
| 7 | Support for attending | X None |
| ' | meetings and/or travel | |
| | meetings and/or traver | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | XNone |
| | pending | |
| | | |
| 9 | Deuticipation on a Data | V. Naza |
| 9 | Participation on a Data | XNone |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X_None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | XNone |
| | | |
| | | |
| 12 | Receipt of equipment, | X None |
| 12 | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| | | |
| 13 | Other financial or non- | XNone |
| | financial interests | |
| | | |
| - | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

Date:_____Oct. 21th, 2022____ Your Name:_ Silin Wang __ Manuscript Title:__Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Natural Science Foundation of China (81770266) | Provide financial or technical support for this article |
| | | Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article |
| | | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone |
|----|---|--------|
| | | |
| | | |
| 5 | Payment or honoraria for | XNone |
| | lectures, presentations, | |
| | speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | X None |
| - | testimony | |
| | | |
| 7 | Support for attending | X None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | XNone |
| | pending | |
| | | |
| 9 | Participation on a Data Safety Monitoring Board or | X None |
| 5 | | |
| | Advisory Board | |
| 10 | | |
| 10 | Leadership or fiduciary role | XNone |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | XNone |
| | | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | X None |
| | | |
| | writing, gifts or other | |
| | services | |
| | | |
| 13 | Other financial or non- | X_None |
| | financial interests | |
| | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

form.

ICMJE DISCLOSURE FORM

Date:____Oct. 21th, 2022____ Your Name:___You Lang Zhou Manuscript Title:__ Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | Time frame: Since the initial planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Natural Science Foundation of China (81770266) | Provide financial or technical support for this article |
| | | Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (HS2019001) | Provide financial or technical support for this article |
| | | Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | XNone | |
|----|--|--------|--|
| | | | |
| | | | |
| 4 | Consulting fees | XNone | |
| | | | |
| _ | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | incettings and/or traver | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | |
| | | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | | V Nono | |
| 11 | Stock or stock options | X_None | |
| | | | |
| 12 | Receipt of equipment, | X_None | |
| 12 | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |
| | | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

form.

ICMJE DISCLOSURE FORM

Date:____Oct. 21th, 2022____ Your Name:___Jiahai Shi Manuscript Title:__ Exploration of the Shared Genes and Signaling Pathways between Lung Adenocarcinoma and Idiopathic Pulmonary Fibrosis.__ Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Natural Science Foundation of China (81770266) Clinical Medical Research Center of Cardiothoracic Diseases in Nantong | Provide financial or technical support for this article Provide financial or technical support for this article |
| | | (HS2019001) Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (TECT-A04) | Provide financial or technical support for this article |
| | | Nantong Key Laboratory of Translational Medicine of Cardiothoracic | Provide financial or technical support for this article |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | XNone | |
|----|---|---------|--|
| | | | |
| | | | |
| 4 | Consulting fees | XNone | |
| | | | |
| F | Deursent er henererie fer | V. Nore | |
| 5 | Payment or honoraria for lectures, presentations, | XNone | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | | X_None | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | X None | |
| 15 | financial interests | | |
| | | | |

The author reports that this work was supported by the National Natural Science Foundation of China (No. 81770266), the Clinical Medical Research Center of Cardiothoracic Diseases in Nantong (No. HS2019001), the Innovation Team of Cardiothoracic Disease in Affiliated Hospital of Nantong University (No. TECT-A04), and Nantong Key Laboratory of Translational Medicine of Cardiothoracic Diseases.

Please place an "X" next to the following statement to indicate your agreement:

form.